Genentech, Inc. (JOBS), Biogen Idec, Inc. (Massachusetts)'s Rituxan Meets Goal in Late Stage Leukemia Trial

SOUTH SAN FRANCISCO, Calif. -Genentech Inc. and Biogen Idec Inc. said Tuesday their cancer drug Rituxan slowed the progress of chronic lymphocytic leukemia in a late stage clinical trial, meeting its primary goal.